Correlation Between Esperion Therapeutics and Corbus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and Corbus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and Corbus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Esperion Therapeutics and Corbus Pharmaceuticals Holding, you can compare the effects of market volatilities on Esperion Therapeutics and Corbus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of Corbus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and Corbus Pharmaceuticals.

Diversification Opportunities for Esperion Therapeutics and Corbus Pharmaceuticals

-0.39

Correlation Coefficient

Esperion Therapeutics  Corbus Pharmaceuticals

Very good diversification

The 3 months correlation between Esperion and Corbus is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and Corbus Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corbus Pharmaceuticals and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with Corbus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corbus Pharmaceuticals has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and Corbus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and Corbus Pharmaceuticals

Given the investment horizon of 90 days Esperion Therapeutics is expected to generate 0.71 times more return on investment than Corbus Pharmaceuticals. However, Esperion Therapeutics is 1.41 times less risky than Corbus Pharmaceuticals. It trades about 0.1 of its potential returns per unit of risk. Corbus Pharmaceuticals Holding is currently generating about -0.16 per unit of risk. If you would invest  191.00  in Esperion Therapeutics on September 13, 2024 and sell it today you would earn a total of  63.00  from holding Esperion Therapeutics or generate 32.98% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Esperion Therapeutics  vs.  Corbus Pharmaceuticals Holding

Esperion Therapeutics

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Esperion Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Esperion Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Corbus Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Corbus Pharmaceuticals Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Esperion Therapeutics and Corbus Pharmaceuticals

The main advantage of trading using opposite Esperion Therapeutics and Corbus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, Corbus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will offset losses from the drop in Corbus Pharmaceuticals' long position.

The idea behind Esperion Therapeutics and Corbus Pharmaceuticals Holding pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.